


REIVINDICACIONES

1. Un compuesto que tiene la fórmula estructural (I):



- 5 o una sal farmacéuticamente aceptable del mismo, en donde:
 A es un alquileo (C_3-C_{10}) saturado o insaturado, lineal o ramificado, fenilalquileo (C_3-C_{10}) o cicloalquilalquileo (C_3-C_{10}) que comprende al menos un grupo $-CH_2-$, en donde uno o más grupos $-CH_2-$ adicionales en A están opcional e independientemente reemplazados con un resto seleccionado entre el grupo que consiste en O, S, NA, CONR, NRCO, SO_2 y SO_2NR y en donde
 10 uno o más de los hidrógenos de A puede estar reemplazado con un grupo independientemente seleccionado entre hidroxilo, halógeno y haloalquilo C_{1-3} ;
 X es un enlace, $C(R^{14})_2$, O, S, SO, SO_2 o NH;
 Y es CR^9 o N, en donde cuando Y es N, Z es CR^{11} y V es CR^{10} ;
 V es CR^{10} o N, en donde cuando V es N, Z es CR^{11} e Y es CR^9 ;
 15 Z es CR^{11} o N, en donde cuando Z es N, V es CR^{10} e Y es CR^9 ;
 R es hidrógeno, alquil C_1-C_6COOH , $COOH$, cicloalquilo C_3-C_6 , alquilo C_1-C_6 , haloalquilo C_1-C_6 , alquil C_1-C_6OH , $COalquilo C_1-C_6$ o $COOalquilo C_1-C_6$;
 R^a es hidrógeno, halógeno, CN, OH, alcoxi C_1-C_6 , alquil $C_1-C_6Oalquilo C_1-C_6$, alquil C_1-C_6COOH , $COOH$, oxo, $COOalquilo C_1-C_6$, alquil $C_1-C_6COOalquilo C_1-C_6$, cicloalquilo C_3-C_6 ,
 20 alquil $C_1-C_6cicloalquilo C_3-C_6$, alquilo C_1-C_6 , -alquil $C_1-C_6Ohaloalquilo C_1-C_6$, haloalquilo C_1-C_6 , alquil C_1-C_6OH , $CON(R^7)(R^8)$, $N(R^7)(R^8)$ o alquil $C_1-C_6N(R^7)(R^8)$ o cuando se toma con R^b forma un cicloalquilo o heterocicloalquilo C_3-C_6 , en donde el cicloalquilo o heterocicloalquilo C_3-C_6 está sin sustituir o sustituido con uno o dos sustituyentes seleccionados entre el grupo que consiste en halógeno, CN, OH, alcoxi C_1-C_6 , alquil $C_1-C_6Oalquilo C_1-C_6$, alquil C_1-C_6COOH ,
 25 $COOH$, oxo, $COOalquilo C_1-C_6$, alquil $C_1-C_6COOalquilo C_1-C_6$, cicloalquilo C_3-C_6 , alquil C_1-

C₆cicloalquilo C₃-C₆, alquilo C₁-C₆, -alquil C₁-C₆Ohaloalquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, CON(R⁷)(R⁸), N(R⁷)(R⁸) y alquil C₁-C₆N(R⁷)(R⁸);

R^b es hidrógeno, halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-

C₆COOH, COOH, oxo, COOalquilo C₁-C₆, alquil C₁-C₆COOalquilo C₁-C₆, cicloalquilo C₃-C₆,

5 alquil C₁-C₆cicloalquilo C₃-C₆, alquilo C₁-C₆, -alquil C₁-C₆Ohaloalquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, CON(R⁷)(R⁸), N(R⁷)(R⁸) o alquil C₁-C₆N(R⁷)(R⁸) o cuando se toma con R^a forma un cicloalquilo o heterocicloalquilo C₃-C₆, en donde el cicloalquilo o heterocicloalquilo

C₃-C₆ está sin sustituir o sustituido con uno o tres sustituyentes seleccionados entre el grupo que consiste en halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-C₆COOH,

10 COOH, oxo, COOalquilo C₁-C₆, alquil C₁-C₆COOalquilo C₁-C₆, cicloalquilo C₃-C₆, alquil C₁-C₆cicloalquilo C₃-C₆, alquilo C₁-C₆, -alquil C₁-C₆Ohaloalquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, CON(R⁷)(R⁸), N(R⁷)(R⁸) y alquil C₁-C₆N(R⁷)(R⁸);

R³ es hidrógeno, halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-

C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH,

15 CON(R⁷)(R⁸), N(R⁷)(R⁸), alquil C₁-C₆N(R⁷)(R⁸), alquil C₁-C₆(OCH₂CH₂)_nN(R⁷)(R⁸) o alquil C₁-C₆Ohaloalquilo C₁-C₆ o cuando se toma con R⁴ forma un cicloalquilo C₃-C₆ o heterocicloalquilo C₃-C₆;

R⁴ es hidrógeno, halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-

C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH,

20 CON(R⁷)(R⁸), N(R⁷)(R⁸), alquil C₁-C₆N(R⁷)(R⁸), alquil C₁-C₆(OCH₂CH₂)_nN(R⁷)(R⁸) o alquil C₁-C₆Ohaloalquilo C₁-C₆ o cuando se toma con R³ forma un cicloalquilo C₃-C₆ o heterocicloalquilo C₃-C₆;

R⁷ es hidrógeno, alquil C₁-C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, COalquilo C₁-C₆ o COOalquilo C₁-C₆;

25 R⁸ es hidrógeno, alquil C₁-C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, COalquilo C₁-C₆ o COOalquilo C₁-C₆;

R⁹ es hidrógeno, halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-

C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH,

CON(R⁷)(R⁸), N(R⁷)(R⁸) o alquil C₁-C₆N(R⁷)(R⁸);

30 R¹⁰ es hidrógeno, halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, CON(R⁷)(R⁸), N(R⁷)(R⁸) o alquil C₁-C₆N(R⁷)(R⁸);

R¹¹ es hidrógeno, halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-

C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, CON(R⁷)(R⁸), N(R⁷)(R⁸) o alquil C₁-C₆N(R⁷)(R⁸);

R¹² es hidrógeno, halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH,

5 CON(R⁷)(R⁸), N(R⁷)(R⁸) o alquil C₁-C₆N(R⁷)(R⁸);

R¹³ es hidrógeno, halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, CON(R⁷)(R⁸), N(R⁷)(R⁸) o alquil C₁-C₆N(R⁷)(R⁸);

cada aparición de R¹⁴ se selecciona independientemente entre el grupo que consiste en hidrógeno,

10 halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, CON(R⁷)(R⁸), N(R⁷)(R⁸) y alquil C₁-C₆N(R⁷)(R⁸);

R¹⁵ es hidrógeno, halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH,

15 CON(R⁷)(R⁸), N(R⁷)(R⁸) o alquil C₁-C₆N(R⁷)(R⁸);

cada aparición de R¹⁶ se selecciona independientemente entre el grupo que consiste en hidrógeno,

halógeno, CN, OH, alcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆, alquil C₁-C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, CON(R⁷)(R⁸), N(R⁷)(R⁸) y alquil C₁-C₆N(R⁷)(R⁸);

20 m es 0 o 1;

n es 1, 2, 3 o 4; y

p es 0 o 1.

2. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del

25 mismo, en donde m es 1, p es 1 y X es O.

3. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo, en donde m es 1, p es 1 y X es un enlace.

30 4. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo, en donde R^a se toma con R^b y forma un heterocicloalquilo.

5. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del

mismo, en donde R^a se toma con R^b y forma un heterocicloalquilo, en donde el heterocicloalquilo es



, y en donde el heterocicloalquilo está sustituido con dos grupos alquilo C_1-C_6 .

5 6. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo, en donde R^a se toma con R^b y forma un cicloalquilo C_3-C_6 .

7. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo, en donde R^a se toma con R^b y forma un cicloalquilo C_3-C_6 , en donde el
10 heterocicloalquilo es



, y en donde el cicloalquilo C_3-C_6 está sin sustituir o sustituido con OH.

8. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo, en donde R^3 es hidrógeno, alquil C_1-C_6 o alquilo C_1-C_6 o cuando se toma
15 con R^4 forma un heterocicloalquilo C_3-C_6 .

9. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo, en donde R^3 es hidrógeno o alquilo C_1-C_6 o cuando se toma junto con R^4 forma un heterocicloalquilo C_3-C_6 .

20 10. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo, en donde R^3 y R^4 son ambos halógeno.

11. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del
25 mismo, en donde R^{15} es hidrógeno o alquilo C_1-C_6 .

12. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo, en donde R^3 y R^4 se seleccionan independientemente del grupo que consiste en hidrógeno, halógeno, OH, alquil C_1-C_6 OH, alquilalcoxi C_1-C_6 , alquil C_1-C_6 Oalquilo C_1-C_6 ,
30 alquilo C_1-C_6 , alquil C_1-C_6 Ohaloalquilo C_1-C_6 , CON(alquilo C_1-C_6)₂, alquil C_1-C_6 N(R^7)(R^8) y alquil C_1-C_6 (OCH₂CH₂)_nN(R^7)(R^8);

R⁷ es hidrógeno, alquil C₁-C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, COalquilo C₁-C₆ o COOalquilo C₁-C₆;

R⁸ es hidrógeno, alquil C₁-C₆COOH, COOH, cicloalquilo C₃-C₆, alquilo C₁-C₆, haloalquilo C₁-C₆, alquil C₁-C₆OH, COalquilo C₁-C₆ o COOalquilo C₁-C₆; y

n es 3.

13. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo, en donde R¹² y R¹³ se seleccionan independientemente del grupo que consiste en hidrógeno, halógeno, OH, alquil C₁-C₆OH, alquilalcoxi C₁-C₆ y alquil C₁-C₆Oalquilo C₁-C₆, alquilo C₁-C₆.

14. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo, en donde X es C(R¹⁴)₂, R¹⁴ se selecciona independientemente entre el grupo que consiste en hidrógeno, halógeno, OH, alquil C₁-C₆OH, alquilalcoxi C₁-C₆, alquil C₁-C₆Oalquilo C₁-C₆ y alquilo C₁-C₆.

15. El compuesto de las reivindicaciones 1-14 o una sal farmacéuticamente aceptable del mismo, en donde Y es CH.

16. El compuesto de las reivindicaciones 1-14 o una sal farmacéuticamente aceptable del mismo, en donde Z es CH.


17. El compuesto de las reivindicaciones 1-14 o una sal farmacéuticamente aceptable del mismo, en donde V es CH.

18. El compuesto de las reivindicaciones 1-14 o una sal farmacéuticamente aceptable del mismo, en donde A es alquilenos (C₃-C₁₀) saturado o insaturado, lineal.


19. El compuesto de las reivindicaciones 1-14 o una sal farmacéuticamente aceptable del mismo, en donde A es alquilenos (C₃-C₁₀) saturado o insaturado, ramificado.






20. El compuesto de las reivindicaciones 1-14 o una sal farmacéuticamente aceptable






del mismo, en donde A es












- 5 21. Un compuesto seleccionado del grupo que consiste en

































































































































































































































































































































, o una sal farmacéuticamente aceptable del mismo.

22. Un compuesto que tiene la fórmula



, o una sal farmacéuticamente aceptable del mismo.


23. Un compuesto que tiene la fórmula



, o una sal farmacéuticamente aceptable del mismo.

5

24. Un compuesto que tiene la fórmula:



, o una sal farmacéuticamente aceptable del mismo.

25. Un método para tratar una infección por *Plasmodium* o para tratar el paludismo,
 10 que comprende administrar a un sujeto que necesita dicho tratamiento una cantidad
 terapéuticamente eficaz de un compuesto de una cualquiera de las reivindicaciones 1-24 o una sal
 farmacéuticamente aceptable del mismo.

26. Un método para inhibir plasmepsina X que comprende administrar a un sujeto que
 15 necesita dicho tratamiento una cantidad terapéuticamente eficaz de un compuesto de una
 cualquiera de las reivindicaciones 1-24 o una sal farmacéuticamente aceptable del mismo.

27. Un método para inhibir plasmepsina IX que comprende administrar a un sujeto
 que necesita dicho tratamiento una cantidad terapéuticamente eficaz de un compuesto de una
 20 cualquiera de las reivindicaciones 1-24 o una sal farmacéuticamente aceptable del mismo.

28. Un método para la doble inhibición de plasmepsina X y plasmepsina X que

comprende administrar a un sujeto que necesita dicho tratamiento una cantidad terapéuticamente eficaz de un compuesto de una cualquiera de las reivindicaciones 1-24 o una sal farmacéuticamente aceptable del mismo.

5 29. El uso de un compuesto o una sal farmacéuticamente aceptable del mismo, de una cualquiera de las reivindicaciones 1-24 para tratar una infección por *Plasmodium* o el paludismo en un paciente que lo necesita.

10 30. El uso de un compuesto o una sal farmacéuticamente aceptable del mismo, de una cualquiera de las reivindicaciones 1-24 para inhibir plasmepsina X en un paciente que lo necesita.

15 31. El uso de un compuesto o una sal farmacéuticamente aceptable del mismo, de una cualquiera de las reivindicaciones 1-24 para inhibir plasmepsina IX en un paciente que lo necesita.

 32. El uso de un compuesto o una sal farmacéuticamente aceptable del mismo, de la reivindicación 1 para inhibir plasmepsina IX y plasmepsina X, en un paciente que lo necesita.

20 33. Una composición farmacéutica que comprende un compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo y un vehículo farmacéuticamente aceptable.

 34. Una composición farmacéutica que comprende un compuesto de la reivindicación 1 y un vehículo farmacéuticamente aceptable.

25 35. Un método para tratar una infección por *Plasmodium* o para tratar el paludismo, que comprende la administración de un compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo y una cantidad eficaz de uno o más agentes antipalúdicos adicionales.

30 36. Un método para el tratamiento del paludismo mediante la inhibición de plasmepsina X, IX y al menos otro mecanismo, que comprende la administración de un compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable del mismo y una

cantidad eficaz de otro agente antipalúdico, en donde el otro agente antipalúdico actúa a través de un mecanismo diferente que inhibe plasmepsina IX o plasmepsina X.